Vita 34 : increases Earnings per Share by 39.8 Percent to EUR 0.23

Vita 34 AG increases Earnings per Share by 39.8 Percent to EUR 0.23

- Total operating revenue increased by 4.9 percent from last year to EUR 11.4 million

- Earnings before interest, taxes, depreciation and amortization (EBITDA) risen to EUR 1.7 million; EBITDA margin improved to 16.8 percent

- Growth strategy pursued consistently: Acquisitions fully consolidated under Vita 34 Group as of September 30, 2015

Leipzig, November 12, 2015 - Vita 34 AG (WKN A0BL84) published its financial figures for the first nine months of 2015 today. They were in line with expectations for fiscal year 2015.

Total operating revenue increased by 4.9 percent from last year, and totaled EUR 11.4 million following EUR 10.8 million in the prior year's reference period. At the same time Vita 34 increased profitability. The earnings before interest, taxes, depreciation and amortization (EBITDA) rose to EUR 1.7 million in the first nine months. Measured against revenues, Vita 34 earned an EBITDA margin of 16.8%. The earnings before interest and taxes (EBIT) of EUR 0.8 million were stable. The period result improved to EUR 0.6 million following EUR 0.4 million in the 2014 reference period. This corresponds to earnings per share of EUR 0.23 (prior year's period: EUR 0.16) and an increase of 39.8 percent as compared with the first nine months of the prior year.

Dr. André Gerth, CEO of Vita 34 AG, commented: 'In the reporting period we consistently pursued our growth strategy and achieved important milestones with four acquisitions - three of them in the third quarter alone. These acquisitions, in particular, had a positive effect on the development of Vita 34. Thus, we were successful in continuing our growth course and, at the same time, in solidifying our market-leading position in Europe.'

At the beginning of the current fiscal year Vita 34 had acquired the assets of Vivocell Biosolutions GmbH & Co KG, Graz. The plant and equipment of Vivocell were fully consolidated in Q1 2015. In July 2015 the acquisition of business interests as well as the voting right majority in our Serbian partner Bio Save, followed. With this investment Vita 34 has strengthened its presence in the Eastern European market. In addition, Vita 34 also acquired business interests and the voting right majority in the Lithuanian company AS 'Imunolita' in July. Thus, in the future Vita 34 will have a direct influence on the operating business and, in particular, will work closely with Imunolita with regard to marketing and sales activities in Lithuania, Estonia and Latvia. Vita 34 opened up the Scandinavian market with the acquisition of the Danish StemCare Group in September 2015. Vita 34 is represented in all of the geographic regions in Europe, and apart from Germany active in a total of 22 countries in Europe and around the world.

'At Vita 34 we will take decisive steps towards the further implementation of our growth strategy in the future. Here, we are placing the focus on the integration of the most recently acquired interests, the furtherance of international expansion into exciting growth markets, as well as the further development of the offering of Vita 34 AG', Dr. André Gerth looks to the future optimistically.

Apart from international expansion, Vita 34 is pursuing the goal of further extending the value chain via the development and introduction of new products for pharmaceutical manufacture, developing Vita 34 into an internationally leading company for the storage and application of stem cells, thereby achieving significant, new market positions. Vita 34 has correspondingly intensified research activities in the reporting period.

The complete interim report for the first nine months of 2015 is available for download as of today on the website at www.vita34group.de in the Investor Relations section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 143,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.